Criticism of the Food and Drug Administration

Ovation Science Announces License Agreement for Its Topical / Transdermal Cannabis Products for Missouri

Retrieved on: 
Thursday, November 2, 2023

VANCOUVER, BC and LAS VEGAS, Nov. 2, 2023 /PRNewswire/ - (CSE: OVAT) (OTCQB: OVATF) – Ovation Science USA Inc. ("Ovation" or the "Company"), with its proprietary topical and transdermal cannabis products powered by its patented skin delivery technology Invisicare®, today announced the signing of an exclusive licensing agreement for Ovation's topical / transdermal formulations for the state of Missouri.

Key Points: 
  • VANCOUVER, BC and LAS VEGAS, Nov. 2, 2023 /PRNewswire/ - (CSE: OVAT) (OTCQB: OVATF) – Ovation Science USA Inc. ("Ovation" or the "Company"), with its proprietary topical and transdermal cannabis products powered by its patented skin delivery technology Invisicare®, today announced the signing of an exclusive licensing agreement for Ovation's topical / transdermal formulations for the state of Missouri.
  • The Company's new licensee is MidWest Roots, LLC ("MidWest"); a company with a 65,000 square foot cannabis processing facility; one of the largest in Missouri.
  • "We are excited to partner with MidWest to bring our innovative topical cannabis products to the Missouri market, said Terry Howlett, President of Ovation.
  • In a recent in-house study, Ovation compared five CBD brand leaders to Ovation Science's topical CBD cream.

KVUE SHAREHOLDERS: Contact Robbins LLP if You Have Incurred Substantial Losses in Kenvue Inc.

Retrieved on: 
Tuesday, October 24, 2023

Kenvue Inc. operates as a consumer health company worldwide.

Key Points: 
  • Kenvue Inc. operates as a consumer health company worldwide.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • You do not have to participate in the case to be eligible for a recovery.

TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline

Retrieved on: 
Saturday, October 21, 2023

In August 2023, TAGRISSO with the addition of chemotherapy also received Breakthrough Therapy Designation from the FDA in this setting.

Key Points: 
  • In August 2023, TAGRISSO with the addition of chemotherapy also received Breakthrough Therapy Designation from the FDA in this setting.
  • Interstitial lung disease (ILD)/pneumonitis occurred in 3.7% of the 1479 TAGRISSO-treated patients; 0.3% of cases were fatal.
  • Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors.
  • For symptomatic congestive heart failure, permanently discontinue TAGRISSO
    Keratitis was reported in 0.7% of 1479 patients treated with TAGRISSO in clinical trials.

KVUE Shareholders: Contact Robbins LLP About Your Rights and Remedies in the Kenvue Inc. Securities Fraud Class Action

Retrieved on: 
Thursday, October 19, 2023

Kenvue Inc. operates as a consumer health company worldwide.

Key Points: 
  • Kenvue Inc. operates as a consumer health company worldwide.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

KVUE Class Action Notice: Robbins LLP Reminds Informs Investors of Lead Plaintiff Deadline in Kenvue Inc. Securities Fraud Class Action

Retrieved on: 
Monday, October 16, 2023

For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Kenvue Inc. Shareholders who want to act as lead plaintiff for the class must file their motion for lead plaintiff by December 8, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1

Retrieved on: 
Monday, October 16, 2023

MIAMI, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Helocyte, Inc. (“Helocyte”), a subsidiary company of Fortress Biotech, Inc. (“Fortress”) (Nasdaq: FBIO), today announced that it executed an exclusive option agreement with City of Hope for patent rights to use Triplex, a cytomegalovirus vaccine, in combination with cytomegalovirus (“CMV”)-specific, Anti-Human Immunodeficiency Virus (“HIV”) Chimeric Antigen Receptor (“CAR”) (collectively, CMV/HIV-CAR) T Cells for the treatment of adults living with HIV. Triplex was initially developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015.

Key Points: 
  • Triplex was initially developed by City of Hope , one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015.
  • Additionally, the California Institute for Regenerative Medicine (“CIRM”) recently awarded a $11.3 million grant to City of Hope to fund a Phase 1 clinical trial.
  • The trial will initially enroll at City of Hope and University of California at San Diego.
  • The study illustrated the potential long-term durability of the combination therapy, which induced therapeutic immune cells to take hold in bone marrow.

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Kenvue Inc. (KVUE)

Retrieved on: 
Wednesday, October 11, 2023

For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Kenvue Inc. Shareholders who want to act as lead plaintiff for the class must file their motion for lead plaintiff by December 8, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer

Retrieved on: 
Monday, October 16, 2023

Importantly, a clinically meaningful PFS benefit was observed across all prespecified subgroups, including patients with central nervous system metastasis.

Key Points: 
  • Importantly, a clinically meaningful PFS benefit was observed across all prespecified subgroups, including patients with central nervous system metastasis.
  • At the time of this analysis, the overall survival (OS) data were immature, however, a favorable trend was observed for TAGRISSO plus chemotherapy.
  • The safety profile of TAGRISSO plus chemotherapy was generally manageable and consistent with the established profiles of the individual medicines.
  • AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

Kenvue Inc. (KVUE) Investor Alert: Robbins LLP Informs Investors of Class Action Filed Against Kenvue Inc.

Retrieved on: 
Thursday, October 12, 2023

Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons who purchased or otherwise acquired Kenvue Inc. (NYSE: KVUE) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Kenvue's initial public offering ("IPO").

Key Points: 
  • Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons who purchased or otherwise acquired Kenvue Inc. (NYSE: KVUE) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Kenvue's initial public offering ("IPO").
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

North America - Healthcare Logistics Market size to grow by USD 18.4 billion from 2022 to 2027, Legislative and regulatory changes supporting pharma growth to drive the growth - Technavio

Retrieved on: 
Monday, October 2, 2023

NEW YORK, Oct. 2, 2023 /PRNewswire/ -- The North America healthcare logistics market is expected to grow by USD 18.4 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Oct. 2, 2023 /PRNewswire/ -- The North America healthcare logistics market is expected to grow by USD 18.4 billion from 2022 to 2027.
  • The adoption of legislative and regulatory changes supporting pharma growth is the key factor driving the market growth.
  • The report analyses the market size and growth and provides accurate predictions on the growth of the market.
  • The healthcare logistics market is estimated to grow at a CAGR of 11.67% between 2022 and 2027.